Close X
Attorney Spotlight

Learn about Richard Arnholt's diverse government contracts practice and why he chose to pursue a career in the legal field. Read more>

Search

Close X

Experience

Search our Experience

Experience Spotlight

In June 2017, Pinnacle Financial Partners, Inc. (NASDAQ: PNFP) closed a $1.9 billion merger with BNC Bancorp (NASDAQ: BNCN) pursuant to which BNC merged with and into Pinnacle. With the completion of the transaction, Pinnacle becomes a Top 50 U.S. Bank. The merger will create a four state footprint concentrated in 12 of the largest urban markets in the Southeast. 

Bass, Berry & Sims has served Pinnacle as primary corporate and securities counsel for more than 15 years and served as counsel on the transaction. Our attorneys were involved in all aspects related to the agreement, including tax, employee benefits and litigation. 

Read more details about the transaction here.

Pinnacle Financial Partners logo

Close X

Thought Leadership

Enter your search terms in the relevant box(es) below to search for specific Thought Leadership.
To see a recent listing of Thought Leadership, click the blue Search button below.

Thought Leadership Spotlight

Regulation A+

It seems that lately there has been a noticeable uptick in Regulation A+ activity, including several recent Reg A+ securities offerings where the stock now successfully trades on national exchanges. In light of this activity, we have published a set of FAQs about Regulation A+ securities offerings to help companies better understand this "mini-IPO" offering process, as well as pros and cons compared to a traditional underwritten IPO.

Read now

Shannon Wiley Outlines CMS Medicaid Drug Rebate Program Final Rule

AHLA Life Sciences and Regulation, Accreditation, & Payment Practice Groups Alert

Publications

February 3, 2016

Bass, Berry & Sims attorney Shannon Wiley outlined the details of the Centers for Medicare & Medicaid Services (CMS) final rule on the Medicaid drug rebate program that goes into effect April 1, 2016. The article focuses on the new rule related to the determination of average manufacturer price (AMP). As stated in the article, "[o]n the issue of AMP calculation, the Final Rule addressed the use of the industry norm 'presumed inclusion' approach versus the proposed 'buildup' approach when calculating sales to wholesalers for drugs distributed to retail community pharmacies."

The full article, "CMS Releases Final AMP Rule," was published by the Life Sciences and Regulation, Accreditation, & Payment Practice Groups of the American Health Lawyers Association (AHLA) on February 1, 2016. The full article is available to members to the AHLA website.


Related Professionals

Related Services

Notice

Visiting, or interacting with, this website does not constitute an attorney-client relationship. Although we are always interested in hearing from visitors to our website, we cannot accept representation on a new matter from either existing clients or new clients until we know that we do not have a conflict of interest that would prevent us from doing so. Therefore, please do not send us any information about any new matter that may involve a potential legal representation until we have confirmed that a conflict of interest does not exist and we have expressly agreed in writing to the representation. Until there is such an agreement, we will not be deemed to have given you any advice, any information you send may not be deemed privileged and confidential, and we may be able to represent adverse parties.